Notice of allowance for patent application regarding RCD405 in the US
Arcede Pharma announces that the patent application for RCD405 has been allowed by a formal notice of allowance from the United States Patent and Trademark Office.The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction (American patent application No: 17/255,264; NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in the US at least until 2039. Patents have previously